Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.

"We are pleased to expand our clinical investigation of IPI-493, as we think its oral availability may provide flexibility in dose and schedule and the potential to be combined with other cancer drugs in earlier lines of therapy," said Julian Adams, Ph.D., president of research and development, Infinity. "Importantly, this study in hematologic malignancies enables us to closely measure potential client protein degradation by IPI-493, which should give us an early read on the therapeutic opportunity with our oral agent."

The primary objectives of this study are to assess safety and tolerability of IPI-493 in patients with advanced hematologic malignancies, and to identify an optimal dose and schedule for subsequent studies. Pharmacokinetic parameters and effects of IPI-493 on pharmacodynamic markers of biological activity will also be assessed. In preclinical models, IPI-493 has demonstrated good oral availability, as well as potent and selective inhibition of the Hsp90 chaperone system. 

Information regarding the trial, including participating clinical trial sites, is available at www.clinicaltrials.gov.

IPI-493 is also being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors. Infinity anticipates reporting data from its Phase 1 program with IPI-493 in 2011.

SOURCE Infinity Pharmaceuticals, Inc.